Article Information
History
- September 23, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Benjamin Meyer#,1,
- Johan Reimerink#,2,
- Giulia Torriani3,
- Fion Brouwer2,
- Gert-Jan Godeke2,
- Sabine Yerly4,
- Marieke Hoogerwerf2,
- Nicolas Vuilleumier5,6,
- Laurent Kaiser4,7,8,
- Isabella Eckerle#,*,3,7,8 and
- Chantal Reusken#,*,2
- 1Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
- 2Centre for Infectious Disease Control, WHO COVID-19 reference laboratory, RIVM, Bilthoven, the Netherlands
- 3Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland
- 4Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
- 5Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, Geneva, Switzerland
- 6Division of Laboratory Medicine, Department of Medicine, Faculty of Medicine, Geneva, Switzerland
- 7Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland
- 8Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
- ↵*corresponding authors: Isabella.Eckerle{at}hcuge.ch, chantal.reusken{at}rivm.nl
↵# contributed equally
Posted September 23, 2020.
Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT)
